Contact: Matt Schutte, Director of Corporate Communications | 614-675-3686
Case's Mark Coticchia joins Omeris Board

Omeris recently announced that Mark E. Coticchia, Vice President for Research and Technology Management at Case Western Reserve University, has joined the organization’s Board of Trustees. Omeris is Ohio’s bioscience membership and development organization.

At Case, Mr. Coticchia is responsible for coordinating the institution’s research agenda and technology commercialization priorities. Prior to joining Case, he was Senior Director of Redleaf Group, Inc., an early stage venture capital firm. As part of the senior management team based in Pittsburgh, Mr. Coticchia’s responsibilities included the development and management of a global university technology transfer and incubator operation that included seed level investment activities.

From 1997-2000, Mr. Coticchia was Director of Technology Transfer at Carnegie Mellon University. He continues to serve as adjunct professor of entrepreneurship at Carnegie Mellon.

The Omeris Board of Trustees also includes: John Bantle, II, PhD, Ohio University; Timothy Biro, Ohio Innovation Fund; Thomas Boat, MD, Cincinnati Children’s Hospital Research Foundation; Mark Collar, Procter & Gamble Pharmaceuticals; Tony Dennis, PhD, Omeris; Jane Henney, MD, University of Cincinnati; Mike Hooven, AtriCure; Peter Kleinhenz, CID Equity Partners; John Rice, PhD, Triathlon Medical Ventures; Richard Rosen, Battelle; Fred Sanfilippo, MD, PhD, The Ohio State University; David Scholl, PhD, Diagnostic Hybrids; Jim Scozzie, PhD, BioEnterprise; and Donald Wetherhold, RxPedite.

Omeris is a non-profit organization supported by the Thomas Edison Program of the Ohio Department of Development. Its mission is to accelerate bioscience discovery, innovation and commercialization of global value, driving economic growth, and improving quality of life in Ohio. Omeris is headquartered in Columbus, with regional business development affiliates in Cleveland, Columbus, Cincinnati and Athens.